Targeting β Catenin in cancer therapy is an area of active research. Strategies include the development of small molecule inhibitors that disrupt the interaction between β Catenin and TCF/LEF transcription factors, the use of antisense oligonucleotides to reduce β Catenin expression, and the design of drugs that promote the degradation of β Catenin. Clinical trials are ongoing to evaluate the effectiveness of these approaches in various cancer types.
